Semaglutide tablets are used to improve blood sugar control in adults with type 2 diabetes
K., Park S
In a glycemic control trial evaluating a dose comparable to the 9 mg dose and the 25 mg semaglutide tablet doses in patients with T2D, 1.3% and 1.9% of patients in the 9 mg and 25 mg semaglutide group, respectively, reported moderate-severe non-proliferative diabetic retinopathy events, and 0% and 0.4% reported proliferative retinopathy events, respectively
WZ: Conceptualization, Investigation, Methodology, Writingoriginal draft
Food Manufacturing Impacts of GLP-1 Use Reduced Demand for High-Calorie, Processed Foods GLP-1 drugs curb appetite and often reduce cravings for calorie-dense, highly processed foods
Cardiovascular Risk and Comorbidity Management Blood Pressure Both Guidelines Individualise BP targets